The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT02251847

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02251847
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02251847. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
Condition
Hypercholesterolemia
Intervention (Drug)
Rosuvastatin/Ezetimibe
Lead sponsor
IlDong Pharmaceutical Co Ltd (class: industry)

Record details

Record id
cardio:ct-nct02251847
Content hash
34476c0b7d2cb15b15b59a55a3af6442d599554da945c6f2760c2de71b0246c5